Title
Pancreas Cancer-Associated Weight Loss.

Permalink
https://escholarship.org/uc/item/31v595ps

Journal
The oncologist, 24(5)

ISSN
1083-7159

Authors
Hendifar, Andrew E
Petzel, Maria QB
Zimmers, Teresa A
et al.

Publication Date
2019-05-01

DOI
10.1634/theoncologist.2018-0266

Peer reviewed
Unintentional weight loss in patients with pancreatic cancer is highly prevalent and contributes to low therapeutic tolerance, reduced quality of life, and overall mortality. Weight loss in pancreatic cancer can be due to anorexia, malabsorption, and/or cachexia. Proper supportive care can stabilize or reverse weight loss in patients and improve outcomes. We review the literature on supportive care relevant to pancreatic cancer patients, and offer evidence-based recommendations that include expert nutritional assessment, counseling, supportive measures to ensure adequate caloric intake, pancreatic enzyme supplementation, nutritional supplement replacement, orexigenic agents, and exercise. Pancreatic Cancer Action Network-supported initiatives will spearhead the dissemination and adoption of these best supportive care practices.

Implications for Practice: Weight loss in pancreatic cancer patients is endemic, as 85% of pancreatic cancer patients meet the classic definition of cancer cachexia. Despite its significant prevalence and associated morbidity, there is no established approach to this disease entity. It is believed that this is due to an important knowledge gap in understanding the underlying biology and lack of optimal treatment approaches. This article reviews the literature regarding pancreas cancer-associated weight loss and establishes a new framework from which to view this complex clinical problem. An improved approach and understanding will help educate clinicians, improve clinical care, and provide more clarity for future clinical investigation.

Prevalence, Classification, and Significance

Weight loss (WL) is highly prevalent among patients with pancreatic cancer (PC) [1, 2], as up to 85% of patients present with WL at diagnosis [3]. Nearly 50% of those with early-stage and locally advanced disease exhibit preoperative WL [4], and 80% will develop progressive WL after diagnosis. There are no approved medical treatments for PC-associated weight loss (PAWL), and commonly used orexigenic agents that stimulate appetite have no definite benefit [5]. Therefore, progressive WL is one of the most distressing and intractable features of PC [6].

Assessment of clinically significant WL in PC is complex and hindered by a lack of standardized definitions and therapeutic strategies [7–9]. The etiologies can be categorized as due to anorexia, malabsorption, and/or cachexia (Fig. 1). Clinically impactful WL in PC is frequently described as cachexia, and classification systems for WL in cancer patients are usually concerned with cancer cachexia. Cachexia is a multifactorial syndrome characterized by progressive involuntary WL, loss of skeletal muscle mass with or without adipose loss, and systemic inflammation [10]. Despite an international consensus statement in 2011 regarding cachexia [10], definitions of clinically important WL in cancer patients remain unclear and heterogeneous [11].

WL in PC patients has predictive and prognostic implications. WL and cachexia predict poor outcomes in all PC stages [4, 9, 12, 13]. Most patients with PC will die with cachexia, and it’s estimated that ~30% will die of cachexia [6, 9–11]. Decreased lean body mass and/or weight are predictors for toxicity [14, 15], mortality [16], postoperative infections, length of hospitalization, and therapeutic intensity [4, 9, 14, 16–21]. WL also correlates with shorter progression-free survival (PFS) and overall survival (OS), decreased response to chemotherapy, lower quality of life (QOL), and declining performance status [3, 10]. In addition,
obesity is a known risk factor for the development of PC [22–25], and its presence at the time of diagnosis is an independent predictor of survival [26]. Patients with low muscle mass and high body mass index (BMI), a condition now described as sarcopenic obesity, exhibit worse outcomes in PC and many other diseases [6, 27, 28].

Optimal approaches to the diagnosis and management of PC weight loss and cachexia are understudied and poorly understood; however, nutritional intervention can improve QOL and OS in advanced PC [29–31]. Recognizing and treating malnutrition in advanced cancer early in the treatment process is essential for improving outcomes [28, 32]. Furthermore, nutritional support in PC is complicated and influenced by many factors including tumor response, diabetes, pain management, altered physiology, and other comorbidities. In this review, we highlight the etiology, assessment, and management of PAWL, provide best supportive care recommendations based on current knowledge (Fig. 2), and bring attention to the gaps.

**Supportive Care Working Group Consensus Process**

The Supportive Care Working Group (SCWG) was formed to establish best supportive care practices across the Precision Promise Consortium (PPC) and to help foster supportive care research. The SCWG consists of scientists, physicians, and a dietician with expertise in pancreatic cancer, nutrition, exercise, cachexia, survivorship, and palliative care. The SCWG compiled all evidence by searching PubMed articles (from 1977 to 2017) on PAWL and other relevant topics. Keywords searched included weight loss, cachexia, anorexia, malabsorption, sarcopenia, pancreatic exocrine insufficiency, malabsorption, pancreatic enzyme replacement therapy, nutrition, and exercise. The group convened quarterly over an 18-month period and corresponded via teleconference bimonthly. The group initially presented the evidence and consensus to the PPC and Steering Committee (SC) in January 2017. The feedback was considered by the SCWG, integrated, and presented back to the PPC and SC in August 2017. Additional feedback was integrated, and the final consensus is presented here.

### Pathogenesis (Causes of PAWL)

We recommend categorizing PAWL into three causes: anorexia, malabsorption/pancreatic exocrine insufficiency, and cachexia/sarcopenia.

#### Anorexia

Anorexia is defined as loss of the desire to eat and is mediated by the inability of the hypothalamus to respond to energy deficit signals [28]. Pain, fatigue, depression, dysmotility, constipation, chemosensory disturbances (changes in smell and taste), vomiting, early satiety, and loss of appetite all contribute to anorexia [10, 33–36]. An important aspect of anorexia is the negative social impact including changes in social encounters and relationships and a sense of helplessness, anxiety, and distress [37, 38]. Patients commonly report distress related to dietary intake and gut symptoms including difficulties with gas, belching, bloating, pain/discomfort, and diarrhea leading to WL [39]. Additionally, current chemotherapy regimens, including gemcitabine/nab-paclitaxel [40], FOLIFIRINOX [41], and nanoliposomal irinotecan/5FU [42], can cause nausea, vomiting, indigestion,
diarrhea, and mouth sores [43] and thus contribute to lower food intake and reduced nutrition.

**Malabsorption/Pancreatic Exocrine Insufficiency**

Pancreatic exocrine insufficiency (PEI), a common complication of PC, occurs when the pancreas is unable to maintain normal digestive function (secretion of proteases, lipase, and amylase), resulting in malabsorption and malnutrition. PEI negatively impacts QOL [44, 45] and is associated with poor survival [44–46]. Additionally, markers of malabsorption and exocrine secretion impairment, such as fecal elastase-1, are strongly correlated with poor survival in PC [46].

Symptoms of malabsorption include increased abdominal bloating or discomfort, excessive gas causing burping or flatulence, indigestion, nausea, delayed gastric emptying/early satiety, changes in bowel movements—increased frequency, light color, floating, frothy, oily, and/or foul smelling, and WL despite intake meeting estimated caloric needs.

**Cachexia and Sarcopenia**

Cachexia results from a complex interaction between tumor, host, and therapy [34, 47] characterized by progressive wasting of skeletal muscle mass and to a lesser extent adipose tissue, occurring even before WL becomes apparent (precachexia) [28, 48]. Preclinical models indicate that chemotherapy and targeted agents can cause cachexia through mitogen-activated protein kinase-dependent muscle atrophy, mitochondrial depletion, and muscle weakness leading to disuse atrophy [49]. Despite the high prevalence and potential for mortality, PC-associated cachexia is diagnosed and treated in a minority of patients [5], as there is no established treatment [50]. The stages of cachexia occur across a spectrum starting with “precachexia” characterized by WL <5%, then “cachexia” associated with systemic inflammation, and ending with “refractory cachexia” defined by a loss of body reserves and rapidly deteriorating nutritional status [10]. Not all patients will progress through all the stages, and no predictive biomarkers have been identified to distinguish patients who will progress [10].

WL is our current measure of cachexia. However, advances in body composition assessment techniques indicate skeletal muscle and adipose tissue may behave independently during WL [51]. In obese patients with cancer, muscle wasting is common and obscured [51]; 40% of PC patients who were found overweight/obese at the time of diagnosis exhibited muscle wasting [6]. Consequently, sarcopenic obesity is linked to functional status, survival, chemotherapy toxicity, and poor outcomes following surgery [52, 53].

**ASSESSMENT OF PAWL**

The morbidity and mortality associated with PAWL compels a comprehensive approach to its assessment and management and should be tailored to each individual. We recommend that all patients be screened for WL, receive clinical and nutritional screening, be assessed for PEI, and receive serum testing. Body composition measurements should be considered in the research setting.

**Screening for WL**

It is important that clinicians assess and record the weight of a patient at presentation and prior to diagnosis. A quick review of WL history can illuminate the extent of PAWL. Assessment of WL over time is one of the standardized
diagnostic characteristics used to identify and document adult malnutrition as recommended by the Academy of Nutrition and Dietetics [54] and the American Society for Parenteral and Enteral Nutrition. Any patient who demonstrates moderate or severe WL and/or evidence of malnutrition or malnutrition risk by these criteria should be directed to a registered dietitian for a more extensive assessment and intervention as described below. The consensus guidelines for interpretation of WL in adults is outlined in Table 1 [55].

**Nutrition Screening and Clinical Assessment**

Nutrition screening using a validated tool allows for identification and referral of at-risk patients to a registered dietitian for complete nutrition assessment and intervention. Screening should be completed on all patients before the start of treatment and at regular intervals such as weekly during radiotherapy, with each chemotherapy visit, and at each surveillance visit [54, 56, 57].

Two nutritional screening tools have been vetted for both inpatient and outpatient use: the malnutrition screening tool (MST) and the patient-generated subjective global assessment (PG-SGA). The MST is a quick, valid, and reliable screening tool. It consists of two questions regarding appetite and recent unintentional WL and has demonstrated high sensitivity and specificity for identification of individuals with or at risk of malnutrition [58]. The PG-SGA is a valid and reliable assessment tool to identify and triage malnourished patients with cancer in both the inpatient and outpatient setting. The abridged PG-SGA forgoes the physical examination used in the PG-SGA and is a practical, informative, and valid tool for use in the outpatient oncology setting for detecting malnutrition [59].

We recommend that patients are screened using one of these tools; those deemed to be at risk for malnutrition should then be referred to a registered dietitian for nutrition assessment. The services of a registered dietitian are important for the early identification of malnutrition and anticipation of nutritional impact on symptoms to help patients maintain weight, stay on their intended treatment, and maintain or improve QOL over the course of their disease.

A full nutrition assessment involves the following elements: obtaining a food history, evaluation of anthropometric measurements, review of medical history, biochemical data, medical tests and procedures, and completion of a nutrition-focused physical assessment [60]. Routine assessment of food intake should include patient estimate of overall food intake and 24-hour food recall [34]. An oncology-focused assessment also involves reviewing the oncologic treatment plan with the goal to determine current and anticipated nutrition issues [54, 57, 61]. This information is all assimilated and used to formulate a plan to address existing and potential influences on malnutrition.

**Assessment for PEI**

Although there are several tests to diagnose pancreatic exocrine insufficiency, their clinical application and use is variable [62, 63]. Definitive identification of PEI in PC patients is challenging; thus, PEI is usually a clinical diagnosis. Direct measures of gastric and duodenal contents such as a secretin-cerulein or secretin-pancreozymin tests are expensive, invasive, and only available at specialized centers [64]. Other tests such as fecal fat test, fecal elastase, and coefficient of fat absorption (CFA) are more clinically available but may be cumbersome [64–66]. Steatorrhea is classically defined as at least 7 grams of fecal fat over 24 hours, in the context of a 72-hour stool test while on 100 grams of fat daily [67]. However, the stool collection and associated diet is inconvenient and difficult for patients. Therefore, fecal elastase measurements are often used to diagnose PEI [67–69]. Fecal elastase is less sensitive (72%) than CFA collection but quite specific (90%). In PC patients, studies have shown a prevalence of PEI varying from 50%–89% when defined by low fecal elastase [46, 70, 71]. Expert opinion is that fecal elastase is appropriate for unresectable patients but is insufficiently sensitive to detect mild-moderate PEI and unsuitable for postpancreaticoduodenectomy patients [72]. Regardless, in standard PC care, these tests are not routinely performed and the diagnosis is established clinically and based on patients’ history and reported symptoms (unintentional WL, change in stool, bloating after meals, etc.). Patients should be clinically assessed for PEI upon diagnosis, at the start of treatment, and on a regular basis throughout the course of their treatment.

**Serum Tests**

There is no widely adopted serologic evaluation of patients with PAWL. However, WL in cancer patients has been associated with markers of inflammation, low levels of serum testosterone in men, and vitamin deficiencies. A more comprehensive serologic evaluation of patients who present with PAWL will likely improve supportive care.

Measuring serum inflammation in PC patients with a Glasgow Prognostic Score (GPS) has shown prognostic significance in several studies [73, 74], and is predictive of surgical outcomes [75, 76]. The GPS and other markers of inflammation are consistently associated with WL and cachexia in cancer patients [77, 78]. GPS is usually scored 0, 1, or 2 by providing 1 point each for C-reactive protein (CRP) >10 and Albumin <3.5. The GPS was recently studied as a predictive factor for response to a novel therapeutic in advanced PC [79]. Recent studies have also suggested that CRP:Albumin ratio and neutrophil:lymphocyte ratio also have prognostic validity [80, 81]. In routine practice, this score could help identify patients at high risk for PAWL and cachexia and could promote early intervention.

Male hypogonadism (MH) is a common complication in advanced cancer [82] and prominent in cancer patients.
[83] with cachexia [84], occurring in more than 70% of these patients [85]. Hypogonadism in cancer cachexia is associated with decreased strength, poor nutritional status [86], decreased performance status, depression, and decreased survival [87, 88]. In a randomized study in cancer patients with fatigue and MH, testosterone replacement improved fatigue and performance status but not QOL [89]. Despite the high prevalence of MH in cancer patients and associated morbidity and mortality, there are no established guidelines for the diagnosis and management of MH in this population [90]. Consensus from the supportive care literature supports the practical application of testosterone replacement in symptomatic patients with MH [91].

There has been little published material regarding serum assessment for vitamin and mineral deficiencies in patients with PC. Most available literature is related to the post-pancreatic resection setting [92] or in the broader topic of PEI from all causes (chronic pancreatitis and cystic fibrosis included) [62]. After resection, reported nutritional deficiencies include fat-soluble vitamins A, D, and E, vitamins B12 and B6, iron, zinc, selenium, biotin, and copper. None of these can be considered diagnostic of malnutrition; however, vitamin D deficiency has been reported in patients with PC and may contribute to poor outcomes [93–95]. These findings were concluded from retrospective analysis, and it is not clear whether vitamin D supplementation improves outcomes. We recommend that vitamin D deficiency should be evaluated and supplemented per physician discretion.

**Body Composition Measurements**

Muscle volumes can be measured and sarcopenia diagnosed using several modalities: computed tomography (CT) or magnetic resonance imaging (MRI); appendicular skeletal muscle index obtained from dual energy x-ray absorptiometry (DEXA); mid-upper-arm muscle area by anthropometry; and whole-body fat-free mass index determined by bioimpedance analysis [10, 96–98]. As CT is commonly used in the diagnosis and treatment of PC, this modality has been used to estimate sarcopenia radiographically by total psoas muscle area and radiodensity [96]. However, psoas muscle measurements do not reflect whole-body muscle; thus, measurements of a whole-body slice at the level of lumbar vertebrae are superior [99]. Morphometric analysis of diagnostic CT or MRI slices can be used to calculate whole-body skeletal muscle and adipose tissue, to assess muscle quality, and to detect presence of myosteatosis. Currently, this can be done using dedicated commercial software such as Sliceomatic or ImageJ. Skeletal muscle and adipose tissue can behave independently during cancer progression and therapy [51, 100], and there may be value in measuring these separate compartments in the research setting.

**Intervention for PAWL**

**Role of the Registered Dietitian**

Dietitians play a central role in the successful management of PAWL. Nutrition interventions for PAWL have improved weight [30], QOL, and outcomes [29, 60, 101]. Dietitians can provide essential dietary suggestions, identify PEI, and provide recommendations for oral nutritional supplementation and specialized nutrition support [102]. Dietitians may also provide more detailed advice on diet and pancreatic enzyme supplementation for management of symptoms of PEI [103–106].

**Pancreatic Enzyme Replacement Therapy**

Pancreatic enzyme replacement therapy (PERT) has demonstrated benefit for PC patients with PEI. Two randomized controlled trials have evaluated the impact of PERT among patients with PEI due to chronic pancreatitis or surgery. These studies demonstrated an increase in fat absorption, reduced stool frequency, improved stool consistency [107–109], and symptom improvement [109]. A previous double-blinded trial of 21 patients with unresectable PC with obstructive jaundice in whom a biliary stent was placed showed that patients randomized to PERT had improved fat absorption and that WL was prevented compared with those who were randomized to placebo [110].

In a retrospective, nonrandomized study of 66 unresectable PC patients receiving PERT with nutritional counseling and palliative care or standard palliative care without PERT, median survival of patients receiving PERT was longer than that of those with standard palliative care (301 days vs. 89 days) [111]. More recently, a randomized study showed an increase in OS in patients randomized to taking enzymes but did not reach statistical significance because of low enrollment rate [112]. Additionally, a prospective study of unresectable patient receiving chemotherapy showed improved changes in BMI and increased OS of patients who received PERT compared with historical controls [113].

In a retrospective, nonrandomized study of 66 unresectable PC patients receiving PERT with nutritional counseling and palliative care or standard palliative care without PERT, median survival of patients receiving PERT was longer than that of those with standard palliative care (301 days vs. 89 days).

These clinical trials evaluating PERT used doses ranging from 40,000 to 72,000 units of lipase for meals and 20,000–36,000 units of lipase per snack. The maximum effective dose is unclear, guidelines vary, and dosing recommendations for PC are not currently indicated on U.S. Food and Drug Administration labels. Enzymes may be dosed based on body weight, fat content of diet, clinical symptoms, degree of steatorrhea present, or general per meal/snack guidelines. The recommended starting dose per meal is 500 lipase units per kg; dosing should be modified as appropriate and should be tailored to individuals as needed to reflect variations in meal sizes and fat content of the diet, clinical symptoms, and the degree of steatorrhea present. Dosages should not exceed 10,000 lipase units per kilogram body weight per day with a maximum of 2,500 lipase units per kilogram per meal [64]. Patients should be instructed to take enzymes at the start of the meal, and if taking multiple capsules, pills should be taken...
Parenteral nutrition may improve weight and maintain or improve performance status in selected patients, but it is not routinely recommended. Careful evaluation should be employed to identify those patients who would benefit and to avoid indiscriminate use of artificial nutrition, especially in cases of futile care and at end of life.

**Pharmacologic Interventions**

Advances in the understanding of etiology of cachexia are leading to pharmaceutical interventions aimed at targets upstream (inhibiting systemic inflammation) or downstream (blocking catabolic pathways, stimulating anabolic pathways, and reducing anorexia) [51]. Appetite stimulants are frequently prescribed for patients with PAWL. Prostaglandins, such as megestrol acetate and corticosteroids, are used as orexigenics [5, 125–127]. Their mechanism of action is also through inhibition of cytokines (including interleukin-6 and tumor necrosis factor) and de-repression of appetite. Anecdotal evidence suggests cannabis improves appetite and food intake in patients with PAWL, and synthetic delta-9-tetrahydrocannabinol, dronabinol, is approved for use in acquired immunodeficiency syndrome-related cachexia and emesis from chemotherapy. However, insufficient data exist for prescribing cannabis for cachexia [128], and a randomized study in advanced cancer patients demonstrated superiority of megestrol acetate over dronabinol [129]. Novel agents for appetite stimulation include ghrelin and ghrelin mimetics, notably anamorelin, for which significant increase in lean body mass was observed in non-small cell lung cancer patients from two phase III trials [130, 131].

Nonsteroidal anti-inflammatory (NSAID) agents, thalidomide, and omega-3 fatty acids modulate cytokine production, thereby inhibiting inflammation. Previous studies of these agents have not shown conclusive benefit, and their routine use is not recommended. Agents targeting the cytokine activin and the related muscle growth inhibitor myostatin have also been evaluated, without report of benefit to date (NCT01433263 and NCT01505530). Newer therapies include monoclonal antibodies against cytokines, including interleukin-1 alpha (NCT03207724) [132]. Combination therapy with NSAID, nutritional supplementation, dietary consultation, and exercise showed benefit in a multicenter, randomized phase II trial of patients with lung or pancreatic cancer, and has now moved to phase III (MENAC, NCT02330926). Investigations of many novel agents are ongoing; however, there are currently no standard systemic therapies for PAWL or PC cachexia [133].

**Exercise**

Physical activity (PA) and exercise could benefit patients with PAWL. In cancer patients, PA has been shown to improve health-related QOL and symptom burden. PA resulted in improved treatment tolerance [134, 135] and is associated with improved PFS and OS [136], suggesting that the benefit of PA is not confined to disease-free survivors.

Gradual resistance training and aerobic exercise can also maintain and restore lean muscle mass [137]. In addition, prescribed exercise resulted in improved appetite and general well-being in patients with advanced cancer receiving palliative care [138]. PA interventions have been deemed safe and feasible in PC patients [139] and may attenuate cachexia by modulating insulin sensitivity and inflammation [140–142]. Progressive postoperative exercise programs have also been demonstrated to be feasible, resulting in lower levels of fatigue and pain and improved perception of general health [143]. In advanced disease, a home-based walking intervention was associated with increased endurance.

**Oral Nutrition Supplements**

If patients show signs of deficiency, have prolonged inadequate intake, or have prolonged malabsorption, clinicians should consider evaluation for deficiencies including vitamins A, D, E, B12, and B6 as well as iron, zinc, selenium, biotin, and copper. Supplements should be recommended for replacement of known deficiencies in the diet or serum levels. Serum values may be rechecked approximately 3 months after attempted repletion. For individuals with inadequate intake of calories and/or protein, nutrition supplement drinks may be recommended as part of the nutritional care plan. Unfortunately, there have been few studies investigating the vitamin deficiencies associated with PEI and the benefit of oral nutrition supplements.

**Specialized Nutrition Support**

Specialized Nutrition Support (SNS) is the use of enteral or parenteral nutrition. Both American and European guidelines for nutrition support recommend against routine use of SNS for oncology patients [116, 117]. However SNS may be necessary for patients with a dysfunction of the gastrointestinal tract such as gastric outlet obstruction or who are severely malnourished and will be undergoing major surgery [116–118]. If SNS is needed, enteral feeding is preferred because of lower risk of infections or other complications [119, 120]. In randomized studies, enteral feeding has shown benefit over other forms of artificial nutrition in patients following a pancreaticoduodenectomy [121].

Parenteral nutrition may improve weight [122] and maintain or improve performance status in selected patients, but it is not routinely recommended. Careful evaluation should be employed to identify those patients who would benefit and to avoid indiscriminate use of artificial nutrition, especially in cases of futile care and at end of life.
and improved symptom burden, with patients increasing their average duration of moderate-intensity exercise [144]. Given the potential for high symptom burden and poor survival outcomes in PC, Groupe Cooperateur Multidisciplinaire en Oncologie has initiated a large randomized trial of adapted physical activity in PC [139]. This study will formally evaluate the benefits of aerobic and resistance exercises on fatigue and health-related QOL, but also investigate the effects of intervention on nutritional status, insulin resistance, cancer treatment tolerance, and survival.

One hundred fifty minutes per week of moderate-intensity aerobic exercise and at least two sessions of resistance training per week is the recommended physical activity for cancer patients and survivors [145–147]. The optimal form and duration of exercise is unclear, and recommendations should be tailored to an individual’s current fitness level, treatment-related late/long-term toxicities, and comorbidities. Referral to physical therapy or other exercise professionals to guide initiation and engagement in physical activity may improve success and thus should be considered for all patients [145–147].

Consensus Statement and Recommendation (Fig. 3)

Slowing WL in patients with PC should improve quality and length of life both directly through maintaining function and indirectly through enhancing treatment delivery and response. In many cases, favorable response to therapy will translate to overall improvement in symptoms and QOL. We recommend all patients who have significant WL and/or evidence of malnutrition be directed to a registered dietician for a more extensive evaluation. As needed, patients should be provided pancreatic enzyme replacement therapy, correction of hormonal and micronutrient deficiencies, and oral nutrition supplementation. Appetite stimulants should be considered. Patients should be warned against inactivity, and moderate-intensity exercise should be encouraged and supported.

**Figure 3.** Consensus recommendations for pancreatic cancer-associated weight loss.

**OVERALL:** Measures to optimize appetite, nutritional intake, micronutrients, and anabolic potential, while reducing disuse and catabolism should be implemented as thoughtfully and aggressively as anti-tumor therapy.

**Dietitian Consultation:** All patients with weight loss and/or evidence of malnutrition risk should be directed to a registered dietitian for extended evaluation and treatment. Assessment of food intake should include patient estimate of overall food intake and 24-hour food recall.

**Pancreatic Enzyme Supplementation:** All patients with evidence or suspicion of pancreatic exocrine insufficiency should be initiated on pancreatic enzymes. The recommended starting dose per meal is 500 lipase units per kg and should be modified as needed based on clinical symptoms, the degree of steatorrhea present and the fat content of the diet. Half of the prescribed individualized dose for a full meal should be taken with snacks. Maximum dose per meal should not exceed 2,500 lipase units per kg of body weight. Patient education should include guidance to take capsules at the start and throughout the meal/snack.

**Exercise:** Patients should be counseled to avoid inactivity. Physical activity goals should be tailored to each individual and in consultation with physical therapists. In general, patients should strive to engage in at least 150 minutes of moderate intensity aerobic exercise and 2 sessions of resistance training per week.

**Oral Nutrition Supplements:** Vitamin and minerals deficiencies should be treated by oral supplements as necessary.

**Systemic Therapy:** Appetite stimulants and non-steroidal anti-inflammatory drugs should be considered.

**Acknowledgments**

We thank Merle Witter for assistance of the preparation of the manuscript. This work was supported by the Pancreatic Cancer Action Network, NIH grants R01 CA122596 and R01 CA194593, the Lustgarten Foundation, Veterans Administration Merit Award I01 BX004177, and the Lilly Endowment, Inc. At the time this manuscript was written, The Precision Promise Consortium was composed of the following members: Andrew Hendifar, Principal Investigator; Richard Tuli, Co-PI (Cedars-Sinai Medical Center); Brian Wolpin, Principal Investigator; Manuel Hidalgo; David Ryan (Dana Farber/ Harvard Cancer Center); Sunil Hingorani, Principal Investigator; Elena Gabriela Chiorean; Andrew Coveler (Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington); Eileen O’Reilly, Principal Investigator; Vinod Balachandran (Memorial Sloan Kettering Cancer Center); Diane Simeone (Perlmutter Cancer Center/NYU Langone Health); Andrew Lowy, Principal Investigator; Paul Fanta; Razelle Kurzrock; Tony Reid (University of California, San Diego); Andrew Ko, Principal Investigator; Eric Collisson;
Margaret Tempero (University of California, San Francisco); Hedy Kindler, Principal Investigator (University of Chicago); Thomas George, Principal Investigator; Jose Trevino (University of Florida); Robert Vonderheide, Principal Investigator; Gregory Beatty (University of Pennsylvania); Vincent Picozzi, Principal Investigator; Margaret Mandelson (Virginia Mason Medical Center); Andrea Wang-Gillam, Principal Investigator; William Hawkins (Washington University); and the Precision Promise Steering Committee (Julie Fleshman, Pancreatic Cancer Action Network; Manuela Hidalgo, Dana Farber Cancer Institute; Sunil Hingorani, Fred Hutchinson Cancer Research Center; Anirban Maity, MD Anderson Cancer Center; Victoria Manax, Pancreatic Cancer Action Network; Lynn Matrisian, Pancreatic Cancer Action Network; Vincent Picozzi, Virginia Mason Medical Center; Diane Simeone, Perlmutter Cancer Center/NYU Langone Health).

REFERENCES

1. Bye A, Jordhoy MS, Skjegstad G et al. Symptoms in advanced pancreatic cancer are more responsive to energy intake. Support Care Cancer 2013;21:219–227.
2. Ferrucci LM, Bell D, Thornton J et al. Nutritional status of patients with locally advanced pancreatic cancer: A pilot study. Support Care Cancer 2011;19:1729–1734.
3. Hendifar A, Chang J, Huang B et al. Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. J Gastrointest Oncol 2018;9:17–23.
4. Bachmann J, Heiligensetzer M, Krakowski-Rooosen H et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008;12:1193–1201.
5. Hendifar AE, Co Tan CR, Yaffe P et al. Evaluating outcomes of pancreatic cancer patients with cachexia. J Clin Oncol 2014;32(suppl 15):e15208a.
6. Tan BH, Birdsell LA, Martin L et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:1734–1741.
7. Bachmann J, Kettker K, Marsch C et al. Pancreatic cancer related cachexia: Influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 2009;9:255.
8. Bachmann J, Buchler MW, Friess H et al. Cachexia in patients with chronic pancreatitis and pancreatic cancer: Impact on survival and outcome. Nutr Cancer 2013;65:827–833.
9. Pausch T, Hartwig W, Hinz U et al. Cachexia but not obesity worsens the postoperative outcome after pancreaticoduodenectomy in pancreatic cancer. Surgery 2012;152(3 suppl 1):S81–S88.
10. Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489–495.
11. Martin L, Senesse P, Gioulbasanis I et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 2015;33:90–99.
12. Hendifar A, Osipov A, Kanhaju P et al. Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma. PLoS One 2016;11:e0152172.
13. Peng P, Hyder Q, Firoozmand A et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg 2012;16:1478–1486.
14. Ali R, Baracos VE, Sawyer MB et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFIRI regimens. Cancer Med 2016;5:607–616.
15. Prado CM, Baracos VE, McCargar LJ et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007;13:3264–3268.
16. Dalal S, Hui D, Bidaut L et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: A pilot study. J Pain Symptom Manage 2012;44:181–192.
17. Kazemi-Bajestani SM, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol 2016;54:2–10.
18. Cousin S, Hollebecque A, Koscielny S et al. Low skeletal muscle is associated with toxicity in patients included in phase I trials. Invest New Drugs 2014;32:382–387.
19. Di Sebastiano KM, Yang L, Zbuk K et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: The relationship with diabetes and anaemia. Br J Nutr 2013;109:302–312.
20. Hubbard TJ, Lawson-McLean A, Fearon KC. Nutritional predictors of postoperative outcome in pancreatic cancer (Br J Surg 2011; 98: 268–274). Br J Surg 2011;98:1032; author reply 1032–1033.
21. Kanda M, Fujii T, Koderay Y et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 2011;98:268–274.
22. Arslan AA, Heilzloesser KJ, Kooperberg C et al. Anthropometric measures, body mass index, and pancreatic cancer: A pooled analysis from the pancreatic cancer cohort consortium (PanScan). Arch Intern Med 2010;170:791–802.
23. Aune D, Greenwood DC, Chan DS et al. Body mass index, abdominal fatness and pancreatic cancer risk: A systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012;23:843–852.
24. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer 2007;120:1993–1998.
25. Michaud DS, Giovannucci E, Willett WC et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001;286:921–929.
26. Yuan C, Bao Y, Wu C et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol 2013;31:4229–4234.
27. Cooper AB, Slack R, Fogelman D et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol 2015;22:2416–2423.
28. Laviano A, Meguid MM, Inui A et al. Therapy insight: Cancer anorexia-cachexia syndrome—when all you can eat is yourself. Nat Clin Pract Oncol 2005;2:158–165.
29. Davidson W, Ash S, Capra S et al. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 2004;23:239–247.
30. Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy—A pilot study. Support Care Cancer 2005;13:270–274.
31. Richter E, Denke A, Klappor S et al. Parenteral nutrition support for patients with pancreatic cancer—Improvement of the nutritional status and the therapeutic outcome. Anticancer Res 2012;32:2111–2118.
32. Vashi PG, Dahik S, Popiel B et al. Longitudinal study investigating quality of life and nutritional outcomes in advanced cancer patients receiving home parenteral nutrition. BMC Cancer 2014;14:593.
33. Uomo G, Gallucci F, Rabitti PG. Anorexia-cachexia syndrome in pancreatic cancer: Recent development in research and management. JOP 2006;7:157–162.

34. Bruea E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol 2000;1:138–147.

35. Wigmore SJ, Plester CE, Richardson RA et al. Changes in nutritional status associated with unrespectable pancreatic cancer. Br J Cancer 1997;75:106–109.

36. Holly EA, Chalila I, Bracci PM et al. Signs and symptoms of pancreatic cancer: A population-based case-control study in the San Francisco Bay area. Clin Gastroenterol Hepatol 2004;2:510–517.

37. Hopkinson JB. The emotional aspects of cancer anorexia. Curr Opin Support Palliat Care 2010;4:254–258.

38. Splinter TA. Cachexia and cancer: A clinician’s view. Ann Oncol 1992;3(suppl 3):25–27.

39. Gooden HM, White KJ. Pancreatic cancer and supportive care—Pancreatic exocrine insufficiency negatively impacts on quality of life. Support Care Cancer 2013;21:1835–1841.

40. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703.

41. Conroy T, Desesigne F, Yhoulou M et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2013;364:1817–1825.

42. Wang-Gillam A, Li CP, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 2016;387:545–557.

43. Nitta H, Baba H, Sugimori K et al. Chemotherapy-induced nausea and vomiting in patients with hepatobiliary and pancreatic cancer treated with chemotherapy: A prospective observational study by the CINV study group. J Gastroenterol 2016;51:1020.

44. Damerla V, Gottlieb V, Larson H et al. Pancreatic enzyme supplementation in pancreatic cancer. J Support Oncol 2008;6:393–396.

45. Park JW, Jang JY, Kim EJ et al. Effects of pancreatectomy on nutritional state, pancreatic function and quality of life. Br J Surg 2013;100:1064–1070.

46. Partelli S, Frulloni L, Minniti C et al. Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Dig Liver Dis 2012;44:945–951.

47. Inui A. Recent development in research and management of cancer anorexia-cachexia syndrome [In Japanese]. Gan To Kagaku Ryoho 2005;32:743–749.

48. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013;10:506–510.

49. Barreto R, Wanig DL, Gao H et al. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget 2016;7:43442–43460.

50. Guillett NP, Mazurak VC, Hebbag G et al. Nutritional interventions for cancer-induced cachexia. Curr Probl Cancer 2011;35:89–90.

51. Fearon KC, Baracos VE. Cachexia in pancreatic cancer: New treatment options and measures of success. HPB (Oxford) 2010;12:323–324.

52. Prado CM, Liefers JF, McCargar LJ et al. Prevalence and clinical implications of sarcomenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008;9:629–635.

53. Pecorelli N, Carrara G, De Cobelli F et al. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Br J Surg 2016;103:434–442.

54. Academy of nutrition and dietetics oncolgy expert work group: Nutrition and the adult oncology patient. Chicago, IL, 2013. www.anecd.org. Accessed December 9, 2016.

55. White JV, Guenter P, Jensen G et al. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: Characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). JPEN J Parenter Enteral Nutr 2012;36:275–283.

56. Cushing SJ, Power DG, Ryan AM. Nutrition assessment in oncology. Top Clin Nutr 2015;30:327–330.

57. Levin R. Nutrition risk screening and assessment of the oncology patient. In: Leser M, Ledesma N, Bergerson S, Truillo E. eds. Oncology Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: Characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). JPEN J Parenter Enteral Nutr 2012;36:275–283.

58. Ferguson M, Capra S, Bauer J et al. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition 1999;15:458–464.

59. Gabrielson DK, Scaf SP, Leung E et al. Use of an abridged scored Patient-Generated Subjective Global Assessment (abPG-SGA) as a nutritional screening tool for cancer patients in an outpatient setting. Nutr Cancer 2013;65:234–239.

60. Mueller C, Compher C, Ellen DM. A.S.P.E.N. clinical guidelines: Nutrition screening, assessment, and intervention in adults. JPEN J Parenter Enteral Nutr 2011;35:16–24.

61. Huhmann MB, August DA. Review of American Society for Parenteral and Enteral Nutrition (ASPEN) clinical guidelines for nutrition support in cancer patients: Nutrition screening and assessment. Nutr Clin Pract 2008;23:182–188.

62. Lindkvist B, Phillips ME, Dominguez-Navarro Prognostic Score is a good predictor of outcome in patients with unresectable pancreatic cancer. Chemotherapy 2010;56:501–506.

63. Glen P, Jamieson NB, McMillan DC et al. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006;6:450–453.

64. Jamieson NB, Denley SM, Logue J et al. A prospective comparison of the prognostic value of tumour and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 2011;18:2318–2328.

65. La Torre M, Negri G, Cavallini M et al. The Glasgow Prognostic Score is a good predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2012;19:2917–2923.

66. McMillan DC, Preston T, Watson WS et al. Relationship between weight loss, reduction of body cell mass and inflammatory response in patients with cancer. Br J Surg 1994;81:1011–1014.

67. Staal-van den Brekel AJ, Dentener MA, Schols AM et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1999;13:2600–2605.

68. Hurwitz HI, Uppal N, Wagner SA et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with cetuximab in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 2015;33:4039–4047.
et al. 25-Hydroxyvitamin D levels and survival in pancreatic cancer. Nutr J 2016;15:17.

80. Liu Z, Jin K, Guo M et al. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol 2017;24:561–568.

81. Wu M, Guo J, Guo L et al. The Creative protein/albunin ratio predicts overall survival of patients with advanced pancreatic cancer. Tumour Biol 2016;37:12525–12533.

82. Strasser F, Palmer JL, Schover LR et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: A pilot study. Cancer 2006;107: 2949–2957.

83. Fuoco D, di Tomasso J, Boulos C et al. Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients. Eacnacmedicscience 2015;9:561.

84. Dev R, Hui D, Del Fabbro E et al. Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer. Cancer 2014;120:1586–1593.

85. Burney BO, Hayes TG, Smiechowska J et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab 2012;97:E700–E709.

86. Garcia JM, Li H, Mann D et al. Hypogonadism in male patients with cancer. Cancer 2006;106: 2583–2591.

87. Del Fabbro E, Hui D, Norruddin ZI et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: A preliminary report. J Pain Symptom Manage 2010;39: 1016–1024.

88. Bilir C, Engin H, Can M et al. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. Med Oncol 2015;32:56.

89. Del Fabbro E, Garcia JM, Dev R et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: A preliminary double-blind placebo-controlled trial. Support Care Cancer 2013;21:2599–2607.

90. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.

91. Dev R, Bruera E, Del Fabbro E. When and when not to use testosterone for palliation in cancer care. Curr Oncol Rep 2014;16:378.

92. Armstrong T, Walters E, Varshney S et al. Deficiencies of micronutrients, altered bowel function, and quality of life during late follow-up after pancreaticoduodenectomy for malignancy. Pancreatology 2002;2:528–534.

93. McGovern EM, Lewis ME, Niesley ML et al. Retrospective analysis of the influence of 25-hydroxyvitamin D on disease progression and survival in pancreatic cancer. Nutr J 2016;15:17.

94. Van Loon K, Owzar K, Jiang C et al. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: Findings from CALGB 93303 (Alliance). J Natl Cancer Inst 2014;106:dju185.

95. Yuan C, Qian ZR, Babic A et al. Prediagnostic plasma 25-hydroxyvitamin D and pancreatic cancer survival. J Clin Oncol 2016;34:2899–2905.

96. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009;3:269–275.

97. Di Sebastiano KM, Mourtzakis M. A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer. Appl Physiol Nutr Metab 2012;37: 811–821.

98. Simons JP, Schols AM, Westerterp KR et al. The use of bioelectrical impedance analysis to predict total body water in patients with cancer cachexia. Am J Clin Nutr 1995;61:741–745.

99. Rutten UG, Ubachs J, Kruijff RFPM et al. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle 2017;8:630–638.

100. Nattenmuller J, Wochner R, Muley T et al. Prognostic impact of CT-quantified muscle and fat distribution before and after first-line chemotherapy in lung cancer patients. PLOS One 2017;12:e0169136.

101. Vashi P, Popiel B, Lammersfeld C et al. Outcomes of systematic nutritional assessment and medical nutrition therapy in pancreatic cancer. Pancreas 2015;44:750–755.

102. Ottery F. Supportive nutritional management of the patient with pancreatic cancer. Oncology (Williston Park) 1996;10:26–32.

103. Phillips ME. Pancreatic exocrine insufficiency following pancreatic resection. Pancreatology 2015;15:449–455.

104. Sikkens EC, Cahen DL, van Eijck C et al. The daily practice of pancreatic enzyme replacement therapy after pancreatic surgery: A northern European survey: Enzyme replacement after surgery. J Gastrointest Surg 2012;16: 1487–1492.

105. Toulji J, Biankin AV, Oliver MR et al. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med J Aust 2010;193:461–467.

106. Optimal care pathway for people with pancreatic cancer. Available at http://www.cancer.nhs.org.au/downloads/health-professionals/optimal-care-pathway/ Optimal_care_pathway_for_people_with_pancreatic_cancer.pdf. Accessed August 4, 2016.

107. Whitcomb DC, Lehman GA, Vasileva G et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic cancer: A double-blind randomized trial. Am J Gastroenterol 2010;105:2276–2286.

108. Gubergrits N, Malecka-Panas E, Lehman GA et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with delayed-release capsules. J Gastroenterol Hepatol 2010;25:1152–1161.

109. Safdi M, Bekal PK, Martin S et al. The effects of oral pancreatic enzymes (Creon 10 capsules) on steatorrhea: A multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas 2006;33:156–162.

110. Bruno MJ, Havercort EB, Tijssen GP et al. Placebo controlled trial of enteric coated pancreatic microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998;42:92–96.

111. Dominguez-Muñoz JE, Nieto L, Iglesias-Garcia J. Pancreatic enzyme replacement therapy and nutritional advice are associated with longer survival in patients with unresectable pancreatic cancer (PC). Pancreas 2013;42: 1347–1347.

112. Zdenkowski N, Radwan G, Pugliese L et al. Treatment of pancreatic insufficiency using pancreatic extract in patients with advanced pancreatic cancer: A pilot study (PICNIC). Support Care Cancer 2017;25:1963–1971.

113. Saito T, Hirano K, Isayama H et al. The role of pancreatic enzyme replacement therapy in unresectable pancreatic cancer: A prospective cohort study. Pancreas 2017;46:341–346.

114. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M et al. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: A randomized, three-way crossover study. Aliment Pharmacol Ther 2005;21:993–1000.

115. Rahib L, Westermann A, Barkin JA et al. Frequency of appropriate use of pancreatic enzyme replacement therapy (PERT) and symptomatic response in pancreatic cancer patients. Abstract presented at: World Congress of Gastroenterology at ACG2017; 2017; Orlando, FL.

116. Arends J, Bachmann F, Baracos V et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017;36:11–48.

117. August DA, Huhmann MB. A.S.P.E.N. clinical guidelines: Nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPNJ Parenter Enteral Nutr 2009;33:472–500.

118. Huhmann MB, August DA. Perioperative nutrition support in cancer patients. Nutr Clin Pract 2012;27:586–592.

119. Chow R, Bruera E, Chiu L et al. Enteral and parenteral nutrition in cancer patients: A systematic review and meta-analysis. Ann Palliat Med 2016;5:30–41.

120. Cotogni P. Enteral versus parenteral nutrition in cancer patients: Evidences and controversies. Ann Palliat Med 2016;5:42–49.

121. Lassen K, Coolen MM, Slim K et al. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced recovery after surgery (ERAS) society recommendations. Clin Nutr 2012;31:817–830.

122. Pelzer U, Arnold D, Govers M et al. Parenteral nutrition support for patients with pancreatic cancer: Results of a phase II studies. BMC Cancer 2010;10:86.

123. Ruggeri EA, Agostini F, Fettucciari L et al. Home artificial nutrition in advanced cancer patients. Tumori 2013;99:218–224.

124. Bozzetti F, Marian L. Perioperative nutritional support of patients undergoing pancreatic surgery in the era of eras. Nutrition 2014;30: 1267–1271.

125. Paulsen Ø, Klepstad P, Rosland JH et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: A randomized, placebo-controlled, double-blind trial. J Clin Oncol 2014;32:3221–3228.
